2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, Cui Y, Li W, Li Q, Yu S, Feng Y, Liu Q, Yang Y, Zhang J, Xu F, Yu Y, Liu T. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications 2024, 15: 7255. PMID: 39179622, PMCID: PMC11343749, DOI: 10.1038/s41467-024-51536-x.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerVariant allele frequencyPhase 2 studyEpidermal growth factor receptorAdverse eventsRAS wild-type metastatic colorectal cancerRAS wt metastatic colorectal cancerSingle-arm phase 2 studyWild-type metastatic colorectal cancerColorectal cancerTreatment-related adverse eventsAnti-PD-1Disease control rateProgression-free survivalRAS wild-typeTumor immune responseCombined treatment regimenWild-typeGrowth factor receptorIrinotecan combinationOverall survivalAnti-EGFRPrimary endpointTumor DNASingle-armCamrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study. Cancer Immunology, Immunotherapy 2024, 73: 124. PMID: 38727837, PMCID: PMC11087418, DOI: 10.1007/s00262-024-03715-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansImmunotherapyIndolesLung NeoplasmsMaleMiddle AgedPyrrolesSulfonamidesConceptsProgression-free survivalDisease control ratePlatinum-doublet chemotherapyOverall survivalAdvanced NSCLCCohort of advanced NSCLC patientsCombination of immune checkpoint inhibitorsMedian progression-free survivalPalmar-plantar erythrodysesthesia syndromeTreatment-related adverse eventsMedian follow-up durationFrequent grade 3Immune checkpoint inhibitorsSafety of camrelizumabTreated with camrelizumabAdvanced NSCLC patientsAdvanced solid tumorsDuration of responseDecreased neutrophil countFollow-up durationTreating multiple cancersMedian DoRCheckpoint inhibitorsMedian OSOS ratesFirst-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Ren S, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal For ImmunoTherapy Of Cancer 2024, 12: e007227. PMID: 38388167, PMCID: PMC10882294, DOI: 10.1136/jitc-2023-007227.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, Non-Small-Cell LungHumansIndolesLung NeoplasmsPyrrolesTumor MicroenvironmentConceptsMetastatic NSCLC patientsDisease control rateProgression-free survivalFirst-line treatmentNSCLC patientsOS ratesPD-L1Overall survivalOpen-labelSafety profileTreatment-related adverse events of grade 3Adverse events of grade 3Combination of immune-checkpoint inhibitorsEvents of grade 3Median progression-free survivalPhase 2 basket trialProgrammed death-ligand 1Treatment-related adverse eventsGrade 5 hemoptysisImmune-checkpoint inhibitorsPD-L1 TPSSafety of camrelizumabSolid Tumors V.1.1Death-ligand 1Response Evaluation Criteria
2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal Of Clinical Oncology 2023, 41: 5163-5173. PMID: 37647576, PMCID: PMC10666986, DOI: 10.1200/jco.22.02630.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDisease ProgressionGemcitabineHumansPancreatic NeoplasmsConceptsProgression-free survivalK-ras wild-type tumorMetastatic pancreatic cancerWild-type tumorsOverall survivalPancreatic cancerK-rasMedian progression-free survivalProgression-free survival timePhase III clinical studiesK-ras wild-typeResponse rateIncidence of adverse eventsDisease control rateSecondary end pointsIII clinical studiesPhase IIb trialMean survival timeMedian OSNimotuzumab groupImproved OSPlacebo groupClinical benefitSafety profileAdverse events